Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and ...

July 29, 2024 First blood test for colorectal cancer offers a less invasive screening option than colonoscopies Guardant Health's Shield test, approved by the FDA, requires less prep work and ...

FDA approves Guardant Health's Shield blood test for colorectal cancer screening in adults 45+, marking the first FDA-approved blood test as a primary CRC screening option. Shield meets Medicare ...

The blood-based colorectal cancer screening program is expected to screen approximately 10,000 people across Abu Dhabi and surrounding regions in its first year. About Guardant Health ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s ...

The FDA has approved a new blood test for colorectal cancer. Shield, made by Guardant Health, is the first approved blood test that is considered a primary screening option for the disease.

The FDA has approved Guardant Health’s Shield blood test for colorectal cancer screening in individuals at average risk aged over 45 years.

Shield is a blood test from Guardant Health for colorectal cancer screening in average-risk individuals 45 and older. CREDIT: Business Wire/Guardant Health.

Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer Aug. 01, 2024 8:30 AM ET Guardant Health, Inc. (GH) ...

PALO ALTO, Calif., July 29, 2024--The FDA has approved the Shield test from Guardant Health, the first blood test approved as a primary screening option for colorectal cancer.

Guardant Health, Inc., a leading precision oncology company, today announced the U.S. Food and Drug Administration has approved the company’ s Shield™ blood test for colorectal cancer ...

PALO ALTO, Calif., August 01, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield™ blood test, recently approved by the U.S. Food and ...